Zepbound Cost Without Insurance: What You Actually Pay in 2026

Lilly advertises Zepbound self-pay "starting at $299" a month. That number is real, and it is also the least useful figure on the page, because $299 buys the 2.5 mg dose — which Lilly's own site says "is a starting dose and is not approved as a maintenance dose." You will not be on it for long. What matters is what the dose you settle on costs, and whether you can hold the discounted price once you get there.

Every figure below comes from Lilly's own published self-pay terms¹, read in August 2026.

The actual dose ladder

Lilly publishes two prices for most doses: a regular self-pay price, and a lower "purchase offer" price with a condition attached. The regular prices for a one-month supply of the single-patient-use KwikPen are:

- **2.5 mg — $299** (starting dose only) - **5 mg — $399** - **7.5 mg — $499** - **10 mg — $699** - **12.5 mg — $699** - **15 mg — $699**

The lower prices are $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 mg, and $449 at 10, 12.5 and 15 mg. So at a common maintenance dose the difference between the advertised price and the regular price is $250 a month — $449 against $699.

The 45-day catch

That $449 is not simply the price. Lilly's purchase-offer terms say you automatically get it on your first purchase of 7.5 mg or above, and then: "To continue to be eligible for this purchase offer, you must complete your refill purchase of the Zepbound single-patient-use KwikPen within 45 days of the delivery/received date of your previous Zepbound single-patient-use KwikPen prescription fill. ... If refill purchase is completed more than 45 days after the delivery/receipt of your previous Zepbound single-patient-use KwikPen prescription, purchase offer will not apply."

Miss the window — a delayed appointment, a supply gap, a month where money is tight — and the price for that fill is the regular one. At 10 mg that is a $250 penalty for being six weeks late instead of six weeks and a day.

This is the same shape as the teaser-rate trap we flag on telehealth programs, dressed differently: the advertised price is real, conditional, and the condition is the part that decides what you pay.

"One month" is 28 days, and that costs you a fill

Lilly defines a month here as "28 days and up to 1 single-patient-use KwikPen." A 28-day cycle is not a calendar month. Thirteen fills fit in a year, not twelve — and the savings card is capped at "a maximum of up to 11 prescription fills per calendar year."

So a full year at 10 mg is roughly thirteen fills, of which the card covers at most eleven. At $449 for the covered fills and $699 for the rest, that is about $6,337 a year, not the $5,388 that twelve times $449 suggests. The card also expires on 12/31/2026.

We apply the same rule to every program we track: never read a seller's "/mo" as a calendar month until you know how many times a year it bills.

Three more things the price depends on

**It is the KwikPen or the vial, not the pen.** Lilly states plainly that "the $299 per month is for the Zepbound KwikPen or vial, not Zepbound single-dose Pen." Same drug, different device, different price.

**It is cash-only, by contract.** The terms require that you "will not seek or accept reimbursement for any out-of-pocket costs ... from any third-party payer," and that you do not apply the spend to a deductible. If you have coverage that might eventually pay, using the self-pay route is a decision, not just a discount.

**Savings are not guaranteed at the till.** Lilly notes savings "may not be applied at the point of sale and may require further action from you" — with a post-transaction reimbursement claim, a portal, and a March 31, 2027 deadline if it goes wrong.

What the compounded route costs, for comparison

Across the 337 programs we track that publish a tirzepatide price (counted August 2026), the median is about $249 a month and the lower quartile is around $199. The cheapest program publishing a genuinely flat, month-to-month tirzepatide rate with no plan term attached runs $133 a month — you can see the whole spread, sorted, on the cheapest tirzepatide ranking.

Against $449 at a maintenance dose, and $699 without the refill window, that is a large gap. It is not a like-for-like gap, and pretending otherwise would be the same trick in reverse:

- Zepbound is an FDA-approved finished medicine². Compounded tirzepatide is not FDA-approved and is not reviewed for safety, effectiveness or quality³. - A compounded program's advertised number carries its own conditions — plan terms, starting-dose rates, membership fees billed beside the drug. We flag those per program, and the honest comparison is our compounded versus brand-name cost breakdown.

Before you pay cash for Zepbound

Price the covered route first. If a commercial plan covers Zepbound, or you qualify for the savings card as an insured patient, a copay usually beats every cash price here — see do GLP-1 savings cards actually lower the price? for who actually qualifies.

If you are genuinely paying cash, the question is not "$299 or $133." It is: what does my maintenance dose cost, can I hold the refill window every single month, and how many times a year will I be billed. Answer those three and the comparison gets easy.

Related reading: Mounjaro vs Zepbound — the same molecule at two prices, Wegovy vs Zepbound on cost and clinical differences, and the rest of our research index.